Substance use disorder

• 1. Introduction

  ›

  Substance use disorder touches the lives of tens of millions of people worldwide, yet it remains one of the most misunderstood conditions in modern medicine. In 2017, an estimated 35 million people around the globe had a substance use disorder tied to illicit drugs alone. That same year, direct deaths from those substances reached 585,000. Alcohol claimed an additional 3 million lives in 2016. These are not abstract statistics. They represent the collapse of families, the loss of careers, and the kind of suffering that ripples outward to entire communities. What exactly is substance use disorder? Why does it grip some people and not others? And what does science now know about treating it?

• 2. Defining the Condition

  ›

  Substance use disorder, or SUD, is defined as the persistent use of drugs despite substantial harm to the individual and to others around them. That word "persistent" is key. It separates SUD from ordinary misuse or experimentation. In 2013, the American Psychiatric Association's DSM-5 merged two older categories, substance abuse and substance dependence, into this single, unified diagnosis. Clinicians now assess severity along a spectrum: mild, moderate, or severe, based on how many of 11 diagnostic criteria a patient meets. Someone meeting two or three criteria receives a mild designation. Four or five criteria point to moderate. Six or more criteria signal severe SUD, and at that level the DSM-5 considers the condition synonymous with what most people call addiction. The World Health Organization's classification system, the ICD-11, takes a different structural approach, dividing the disorder into just two categories: a harmful pattern of use, and substance dependence. Both systems reflect the same underlying reality. Substance use disorder is not a character flaw or a lapse of willpower. It is a clinical condition with measurable symptoms, a spectrum of severity, and recognized treatment protocols. The drug classes most commonly involved include alcohol, cannabis, opioids, stimulants such as nicotine and cocaine, amphetamines, benzodiazepines, and barbiturates.

• 3. Why Some People and Not Others

  ›

  Children born to parents with substance use disorder face roughly twice the risk of developing the condition themselves compared to children of parents without it. That doubled risk reflects the tangled interaction of genetics, environment, and learned behavior all at once. Biological factors are only part of the picture. Adverse childhood experiences, documented in a 2021 study, show a direct link between early trauma and later substance use. The brain systems involved in reward, executive function, stress, mood, and self-awareness undergo long-lasting changes in people with moderate or severe SUD, which helps explain why willpower alone rarely resolves the condition. Social determinants carry significant weight as well. Among older adults, being divorced, separated, or single, lacking religious affiliation, facing involuntary retirement, or experiencing homelessness all correlate with higher rates of alcohol problems. Unemployment feeds the cycle in a particularly vicious way. Job loss generates stress and sometimes depression, which can increase substance use, which in turn makes sustained employment harder to maintain. Psychological risk factors add another layer. Beginning alcohol or drug use in the teen years raises the odds of developing SUD in adulthood. Being male, being under 25, having other mental health disorders, high impulsivity, and low conscientiousness combined with high sensation-seeking and neuroticism also feature prominently in the research. The coexistence of SUD with another mental health disorder is common enough that clinicians have a formal term for it: co-occurring disorders.

• 4. The Body and Mind Under Strain

  ›

  Anxiety and depression are closely linked to greater substance use over time, particularly in adolescents. Some young people who use substances can reach clinical levels of anxiety and depression, measurable through tools like the PHQ-4. Hallucinations tied to substances such as cannabis may also contribute to the onset of disorders including schizophrenia. The physical toll spreads across virtually every organ system. Depending on the substance, the body may face liver failure, kidney failure, hypertension, memory loss, osteoporosis, immunodeficiencies, or the risk of transmitting HIV through shared needles. Heavy alcohol withdrawal carries its own acute danger: a condition known as delirium tremens, a potentially fatal withdrawal syndrome that requires medical supervision to manage safely. Behavioral changes often surface before a person or their family recognizes what is happening. Absences from school or work, shifts in appetite and sleep, personality changes, and mood swings can all signal early stages of SUD. In severe cases, the disorder can fracture families through divorce or trigger intervention by agencies such as Child Protective Services. The source material notes, plainly, that SUD can even result in suicide.

• 5. Measuring the Scale

  ›

  In 2020, roughly 14.5% of Americans aged 12 or older had experienced a substance use disorder in the past year. Just over 5% of that same population met criteria for alcohol use disorder, while approximately 3% had an illicit drug use disorder. The highest rates of illicit drug use disorder fell among those aged 18 to 25, at roughly 7%. Drug overdose deaths in the United States surpassed 72,000 in 2017, a threefold increase from 2002. That figure does not include the 2,366 alcohol overdose deaths recorded separately by the CDC that same year. Synthetic opioids, typically involving fentanyl, contributed to nearly 30,000 deaths per year, with death rates from synthetic opioids rising 22-fold between 2002 and 2017. Heroin and other natural and semi-synthetic opioids together contributed to roughly 31,000 overdose deaths. Cocaine accounted for roughly 15,000. Methamphetamine and benzodiazepines each contributed to roughly 11,000. Alcohol-related deaths account for more than 88,000 lives annually. Tobacco, the leading cause of preventable death in the United States, is responsible for more than 480,000 deaths each year. The combined financial cost of these harms exceeds $420 billion annually, with more than $120 billion falling directly on the healthcare system. In Canada, approximately one in five Canadians aged 15 and older will experience a substance use disorder in their lifetime. In Ontario, the disease burden of mental illness and addiction is 1.5 times higher than all cancers combined and more than seven times that of all infectious diseases.

• 6. Diagnosis and Screening

  ›

  Diagnosis of SUD typically involves an in-depth examination, usually conducted by a psychiatrist, psychologist, or drug and alcohol counselor. The 11 DSM-5 diagnostic criteria group into four broad areas: loss of control over use, strain on interpersonal relationships, hazardous use, and pharmacological effects such as tolerance and withdrawal. The criteria include nuance. A person taking opioids exactly as prescribed may experience tolerance and withdrawal without meeting criteria for SUD, provided no other symptoms are present. Several validated screening tools exist. For adolescents, the CRAFFT has been widely used. For adults, tools like the CAGE, AUDIT, and DALI provide structured assessments. More recent additions include statistical software built on the Data Driven Diagnostic Method. For tobacco and alcohol specifically, the S2BI, BSTAD, and TAPS offer focused screening aligned with DSM categories. Urine and blood tests can confirm the presence of substances and establish a baseline for monitoring progress, but they measure recent use rather than chronic dependence, so they are not recommended as primary screening instruments. Screening adolescents presents a particular logistical challenge. Research regulations require parental consent for participants under 18, yet the behaviors being studied are often ones a young person would not disclose to a parent. This creates a selection bias: participants whose parents consented tend to be less likely to have substance use problems in the first place.

• 7. Paths to Treatment

  ›

  About 11% of Americans with substance use disorder seek treatment, and 40-60% of those who do relapse within a year. Those figures are sobering, but they have not stopped researchers and clinicians from building a substantial body of evidence around what works. Cognitive behavioral therapy, known as CBT, helps people identify and change thought patterns that drive harmful behavior. Motivational interviewing is designed to engage patients who are ambivalent about change. Combined behavioral intervention draws on multiple approaches at once, using functional analysis to identify high-risk situations tied to specific substances. From behavioral psychology, approaches such as community reinforcement, contingency management, and behavioral marital therapy have all shown evidence of effectiveness. On the medication side, five medications are approved in the United States to treat alcohol and opioid use disorders. No approved medications exist yet for cocaine or methamphetamine. Methadone and disulfiram are among the medications used to help patients function without illicit opioids or alcohol. Research has documented that medication-assisted treatment reduces illicit drug use, cuts overdose deaths, improves retention in treatment programs, and reduces HIV transmission. Withdrawal management, the medical and psychological care given when someone stops using, can require medical detoxification in severe cases, especially for heavy alcohol users at risk of delirium tremens.

• 8. Vaccines and Privacy

  ›

  Vaccines for addiction have been under investigation since the early 2000s. The underlying concept is to condition the immune system to disable or destroy the molecules of an addictive substance before they can reach the brain. NicVAX, developed by Nabi Biopharmaceuticals of Rockville, Maryland, with support from the U.S. National Institute on Drug Abuse, targets nicotine. It contains the hapten 3'-aminomethyl nicotine attached to Pseudomonas aeruginosa exotoxin A. TA-CD, developed by the Xenova Group, targets cocaine by combining norcocaine with inactivated cholera toxin. It works by prompting antibodies to attach to cocaine molecules, preventing them from crossing the blood-brain barrier and blocking the dopamine release in the mesolimbic reward pathway that produces the euphoric effect. Critically, TA-CD does not reduce the desire for cocaine; it blocks only the physical effect. TA-NIC targets nicotine through a similar antibody mechanism. As of September 2023, a vaccine tested against heroin and fentanyl was reported to be moving toward trials against oxycontin. On the legal side, treatment records for SUD in the United States have carried heightened federal privacy protections under 42 CFR Part 2 since 1975, restricting disclosure more strictly than ordinary medical records and barring their use in criminal proceedings without a court order. In February 2024, the U.S. Department of Health and Human Services issued a final rule aligning those protections more closely with standard HIPAA rules, effective April 2024, with full compliance required by February 2026. Supporters argued the change would improve care coordination; critics warned it could expose patients to discrimination or legal jeopardy, a tension that the ongoing evolution of addiction medicine will have to navigate alongside the science itself.